tbuckley/cabot-search huggingface dataset:
Incidence of side effects in patients on long-term lithium therapy
Authors: S Bone, S P Roose, D L Dunner, R R Fieve
Journal: American Journal of Psychiatry (1980)

Lithium carbonate is used increasingly in clinical practice for the treatment of acute mania (1) and the prophylaxis of bipolar illness (2). Because of concern about the seriousness and frequency of side effects, lithium is often discontinued prematurely, maintained at less than optimal levels, or not used when it should be. We conducted a survey of the patients at the New York State Psychiatric Institute Lithium Clinic to evaluate the instance and severity of several lithium side effects. We hypothesized that mood and the concomitant use of other psychiatric medications such as antipsychotics and tricyclic antidepressants would be positively correlated with the severity of reported side effects.
Thigh Splints in a Young Female Soccer Player
Authors: A. CAHID CIVELEK, WILLIAM W. SCOTT, BRUCE A. URBAN, STEVEN A. LIETMAN
Journal: Clinical Nuclear Medicine (2001)

CAHID CIVELEK, A. M.D.; SCOTT, WILLIAM W. Jr., M.D.; URBAN, BRUCE A. M.D.; LIETMAN, STEVEN A. M.D. Author Information
Platelet MAO activity in schizophrenia and other psychiatric illnesses
Authors: J Sullivan, C N Stanfield, C Dackis
Journal: American Journal of Psychiatry (1977)

Previous reports have indicated that platelet MAO activity is low in some schizophrenic and other psychiatric patients. However, other studies have not been able to replicate this phenomenon. This study supportsthe previous observations of low enzyme activity in some chronic schizophrenic patients. The authors discuss the thesis that low platelet MAO activity may be a biochemical marker for vulnerability to psychiatric illness.
Arrhythmia prophylaxis: Long-term suppressive medication.
Authors: Lovell Rr
Journal: Circulation (1975)

The author describes the notions that led to initiation of controlled trials of long-term medication with antiarrhythmic drugs following myocardial infarction, and reviews reports of controlled trials with diphenylhydantoin, alprenolol, and procaine amide. It is concluded that, so far as possible widespread prophylactic use of these drugs to prevent sudden death is concerned, diphenylhydantoin has no place, while procaine amide cannot be evaluated on a large scale because of the frequency with which it causes serious adverse reactions. There is no bar to an extended trial with alprenolol or comparable beta-blocking drugs. The author believes that nonspecific prophylactic long-term use of antiarrhythmic drugs to prevent sudden coronary death outside the hospital is unlikely to prove rewarding.
Alpha<sub>1</sub>-Antitrypsin Deficiency
Authors: James O. Morse
Journal: New England Journal of Medicine (1978)

Relation of the Defect to Pulmonary DiseaseIt is clear that severely deficient subjects of phenotype PiZ and probably PiSZ are much more susceptible to the development of emphysema or chronic bronchitis (or both) than the general population, the large majority of whom are of phenotype PiM.57,58 The continuing question has been whether those with lesser degrees of deficiency, mainly PiMZ or PiMS, are at any greater risk for the development of such obstructive lung diseases than those of phenotype PiM.Initially, the problem was attacked by measurement of alpha1-antitrypsin levels in groups of patients with pulmonary diseases, but the . . .
Commentary on “Tumor Heterogeneity and the Biology of Cancer Invasion and Metastasis”
Authors: Isaiah J. Fidler
Journal: Cancer Research (2016)

See related article by Fidler, [Cancer Res 1978; 38:2651–2660][1] .

Visit the Cancer Research 75th Anniversary [timeline][2].

Metastasis, the transfer of disease from one organ or part to another not directly connected to it, is the major cause of cancer-related deaths ([1][3]). The pathogenesis
Postchemotherapy surgery in nonseminoma.
Authors: E W Steyerberg, H J Keizer, D T Sleijfer
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.9.3165 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9294480 Postchemotherapy surgery in nonseminoma. E W SteyerbergxE W SteyerbergSearch for articles by this author , H J KeizerxH J KeizerSearch for articles by this author , D T SleijferxD T SleijferSearch for articles by this author https://doi.org/10.1200/JCO.1997.15.9.3165 PDF "Postchemotherapy surgery in nonseminoma.." Journal of Clinical Oncology, 15(9), pp. 3165–3166© 1997 by American Society of Clinical Oncology
RO-15CHALLENGES FOR SENDING PATIENTS WITH MEDULLOBLASTOMA FOR PROTON RADIOTHERAPY ABROAD
Authors: Yasmin Lassen-Ramshad, Anita Mahajan, Leif Christensen, Gorm von Oettingen, Benedicte Parm Ulhøi, Christine Dahl, Niels Clausen
Journal: Neuro-Oncology (2016)
LG-68THE GENETIC AND CLINICAL LANDSCAPE IN PEDIATRIC LOW GRADE GLIOMA; PRELIMINARY RESULTS FROM PLGG TASKFORCE
Authors: Michal Zapotocky, Alvaro Lassaletta, Scott Ryall, Anthony Arnoldo, Matthiew Mistry, Ana Guerreiro-Stucklin, Nataliya Zhukova, Vijay Ramaswamy, Ute Bartels, Annie Huang, Suzanne Laughlin, Peter Dirks, Eric Bouffet, Uri Tabori, Cynthia Hawkins
Journal: Neuro-Oncology (2016)
The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase‐1 antibodies
Authors: N. Hunzelmann, G. Riemekasten, M.O. Becker, P. Moinzadeh, A. Kreuter, I. Melchers, U. Mueller‐Ladner, F. Meier, M. Worm, H. Lee, I. Herrgott, C. Pfeiffer, G. Fierlbeck, J. Henes, A. Juche, G. Zeidler, H. Mensing, C. Günther, M. Sárdy, H. Burkhardt, M. Koehm, K. Kuhr, T. Krieg, C. Sunderkötter
Journal: British Journal of Dermatology (2015)
CR-11PEDIATRIC ADAMANTINOMATOUS CRANIOPHARYNGIOMA CYST FLUID DEMONSTRATES A PRO-INFLAMMATORY MILIEU
Authors: Andrew Donson, Andrea Griesinger, Vladimir Amani, Richard C.E. Anderson, Toba N. Niazi, Michael H. Handler, Nicholas K. Foreman, Todd C. Hankinson
Journal: Neuro-Oncology (2016)

CR-11. PEDIATRIC ADAMANTINOMATOUS CRANIOPHARYNGIOMA CYST FLUID DEMONSTRATES A PRO-INFLAMMATORY MILIEU Andrew Donson2, Andrea Griesinger2, Vladimir Amani2, Richard C.E. Anderson4, Toba N. Niazi3, Michael H. Handler1,2, Nicholas K. Foreman1,2, and Todd C. Hankinson1,2; Children’s Hospital Colorado, Aurora, CO, USA; University of Colorado School of Medicine, Aurora, CO, USA; Nicklaus Children’s Hospital, Miami, FL, USA; Morgan Stanley Children’s Hospital of New York-Presbyterian, New York, NY, USA BACKGROUND: The cyst component of pediatric adamantinomatous craniopharyngioma (ACP) often exerts substantial mass effect, grows unpredictably, and is poorly responsive to radiation therapy. Current cyst-directed therapies mandate surgical intervention. An improved understanding of the drivers of ACP cyst growth may allow for the identification of systemic therapies that can control cyst expansion and improve tumor control and/or our ability to safely undertake radical tumor resection. METHODS: Milliplex cytokine expression analysis was used to compare the cytokine milieu of ACP cyst (n 1⁄4 5) to another common cyst generating pediatric brain tumor, Juvenile Pilocytic Astrocytoma (JPA, n 1⁄4 5). The ratio of cytokine levels in the 2 tumor types was compared. RESULTS: Compared to JPA cysts, all ACP specimens showed a highly pro-inflammatory cytokine pattern. Among the cytokines with elevated expression level ratios in ACP, relative to JPA, were IL-6 (353.9, p 1⁄4 1.23x10); IL-8 (57.6, p 1⁄4 0.04); IL-10 (35.5, p 1⁄4 0.003); TNF-a (8.21, p 1⁄4 0.01); and IL-1b (3.65, p 1⁄4 0.005). CONCLUSIONS: ACP cyst fluid appears to be characterized by a highly pro-inflammatory cytokine expression pattern. Understanding the cellular source of these cytokines and the efficacy of selective cytokine blockade may represent an opportunity for therapeutic intervention. Neuro-Oncology 18:iii18–iii23, 2016. doi:10.1093/neuonc/now068.11 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
MB-28MicroRNA EXPRESSION IS HIGHLY SUBGROUP SPECIFIC IN MEDULLOBLASTOMA
Authors: Sivan Gershanov, Shalom Michowiz, Orit Barinfeld, Mali Salmon-Divon, Nitza Goldenberg-Cohen, Helen Toledano
Journal: Neuro-Oncology (2016)

MB-28. MicroRNA EXPRESSION IS HIGHLY SUBGROUP SPECIFIC IN MEDULLOBLASTOMA Sivan Gershanov1,2, Shalom Michowiz3,4, Orit Barinfeld2,3, Mali Salmon-Divon1, Nitza Goldenberg-Cohen3,4, and Helen Toledano3,4; Ariel University, Ariel, Israel; Felsenstein Medical Research Center, Petah-Tiqwa, Israel; Tel-Aviv University, Tel-Aviv, Israel; Schneider Children’s Medical Center of Israel, Petah-Tiqwa, Israel Medulloblastoma (MB), the commonest malignant brain tumor of childhood, is divided into four tumor subgroups representing distinct clinical and molecular entities. MicroRNAs (miRNAs) are involved in carcinogenesis and tumor progression by regulating post-transcriptional gene expression. However, our understanding of the miRNA-mRNA regulatory network is incomplete. The aim of the study is to identify novel miRNA subgroup biomarkers and their target mRNAs for rapid and specific diagnosis and future targeted therapy. With this aim, integrated whole transcriptome mRNA and miRNA expression analysis was performed on primary tumor samples collected from 10 MB patients. 867 mature miRNAs were identified in at least a single MB sample, of them 462 were common to all 4 subgroups. 25 (2.5%) of all expressed miRNAs appeared to be significantly differentially expressed between the MB subtypes (FDR , 0.1). Namely, upregulation of hsa-miR-224-5p and hsa-miR-449c-5p was found exclusively among WNT, while downregulation of hsa-miR-135b-5p characterized SHH. Among groups 3 and 4, hsa-miR-20a-5p was upregulated or downregulated, respectively. RNA-seq from the same tumor samples identified 500 genes that vary between subtypes (q value ,0.05), among which 69 (13.8%) have anticorrelated miRNA-mRNA interactions with the 25 detected miRNA biomarkers. The predicted mRNAs targets of these miRNAs are associated with different signaling pathways, known to have a role in MB biology. Our study demonstrates that miRNAs are readily detectible and are highly specific to distinct MB subgroups. Understanding the involvement of miRNAs and their targets in MB related signaling pathways may improve diagnosis and advance the development of targeted treatment for MB. Neuro-Oncology 18:iii97–iii122, 2016. doi:10.1093/neuonc/now076.26 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony- stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study
Authors: A Ganser, A Lindemann, OG Ottmann, G Seipelt, U Hess, G Geissler, L Kanz, J Frisch, G Schulz, F Herrmann
Journal: Blood (1992)
EPT-11THE POTENTIAL ROLE OF REGADENOSON TO TRANSIENTLY DISRUPT THE BLOOD-BRAIN BARRIER AND IMPROVE TEMOZOLOMIDE DELIVERY TO BRAIN TUMORS
Authors: Sadhana Jackson, Anna Piotrowski, Jon Weingart, Thura Abd, Richard George, Allison Hays, Xiaobu Ye, Nicole Anders, Michelle Rudek, Stuart Grossman
Journal: Neuro-Oncology (2016)
Interaction of serum ferritin and body mass index in patients with chronic hepatitis B: Improved prediction of cirrhosis
Authors: Kris V. Kowdley, James Nelson
Journal: Hepatology (2012)

We would like to thank Paul etal. for their interest in our article.1 Here, they report on a predicted positive relationship between body mass index (BMI), serum ferritin (SF), and transient elastography score (TES) in chronic hepatitis B patients using regression modeling. Furthermore, using interaction regression models, they found that, among subjects with BMI >28 kg/m2 increased SF was associated with increased TES, including a higher probability of TES above the cirrhosis cutpoint of >13 when SF levels were >650 µg/L. In our study, we found that both BMI and SF >1.5 times the upper limit of normal (ULN) were independent predictors of advanced fibrosis using multivariate stepwise logistic regression analysis, including the following variables, selected a priori, known to be associated with severity of nonalcoholic fatty liver disease: age at biopsy; sex; BMI; presence of diabetes; and alanine aminotransferase. Despite finding that both BMI and SF >1.5 times the ULN independently predicted advanced fibrosis, when we conducted additional interaction regression analyses with regard to BMI, SF, and advanced fibrosis to see whether similar relationships were also evident in our cohort, we did not find a significant interaction of BMI and SF on advanced fibrosis. In fact, we found a significantly lower BMI in subjects above SF >1.5 versus SF ≤1.5 times the ULN (32.6 ± 5.5 versus 34.4 ± 6.5; P = 0.004). The reason for this lies within our study cohort; our cohort consisted of 141 premenopausal women who had a significantly higher mean BMI (36.0 kg/m2) than the rest of the cohort, but a lower SF level (139 ng/mL) as a result of ongoing menses (Table 1). Furthermore, this group accounted for only 12% of subjects with advanced (stage 3 and 4) fibrosis. Thus, in analyzing our total cohort for a statistical interaction of BMI/SF on fibrosis, this subgroup of premenopausal women, with a higher mean BMI, likely biased any potential positive effects of BMI and SF upon fibrosis. To investigate this further, when we repeated the interactive regression models individually in each group shown in Table 1 we did find a small, but significant, interaction of SF and BMI in male subjects alone (odds ratio: 1.0003; P = 0.028). We would like to also note that there are quite a few differences between our cohort and that of Paul etal.; in addition to being different diseases, our cohort had fewer males (37% versus 54%), higher BMI (34.6 versus 25.4), and higher SF (males, 263 versus 205 ng/mL; females, 110 versus 88 ng/mL).
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Authors: Steven P. Marso, Gilbert H. Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F.E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R. Poulter, Lasse S. Ravn, William M. Steinberg, Mette Stockner, Bernard Zinman, Richard M. Bergenstal, John B. Buse
Journal: New England Journal of Medicine (2016)

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjustments for multiplicity were performed for the prespecified exploratory outcomes.A total of 9340 patients underwent randomization. The median follow-up was 3.8 years. The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P=0.01 for superiority). Fewer patients died from cardiovascular causes in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93; P=0.007). The rate of death from any cause was lower in the liraglutide group (381 patients [8.2%]) than in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P=0.02). The rates of nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure were nonsignificantly lower in the liraglutide group than in the placebo group. The most common adverse events leading to the discontinuation of liraglutide were gastrointestinal events. The incidence of pancreatitis was nonsignificantly lower in the liraglutide group than in the placebo group.In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048.).
HG-95INTEGRATED MOLECULAR META-ANALYSIS OF 1000 PAEDIATRIC HIGH GRADE GLIOMA AND DIPG
Authors: Alan Mackay, Anna Burford, Janat Fazal Salom, Lynn Bjerke, Mara Vinci, Valeria Molinari, Kathryn Taylor, Meera Nandhabalan, Sergey Popov, Kun Mu, Saoussen Trabelsi, Dorra H'mida-Ben Brahim, Rui Reis, Andrew Moore, Ho-Keung Ng, Andre von Bueren, Michael Baudis, Chris Jones
Journal: Neuro-Oncology (2016)
Avoidance of Carotid Ultrasound in Syncope—Keeping It Simple
Authors: Sarah J. Burns, Jonathan D. Orner, Mary E. Lacy
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Elimination of<i>Taenia solium</i>Transmission in Northern Peru
Authors: Hector H. Garcia, Armando E. Gonzalez, Victor C.W. Tsang, Seth E. O’Neal, Fernando Llanos-Zavalaga, Guillermo Gonzalvez, Jaime Romero, Silvia Rodriguez, Luz M. Moyano, Viterbo Ayvar, Andre Diaz, Allen Hightower, Philip S. Craig, Marshall W. Lightowlers, Charles G. Gauci, Elli Leontsini, Robert H. Gilman
Journal: New England Journal of Medicine (2016)

Taeniasis and cysticercosis are major causes of seizures and epilepsy. Infection by the causative parasite Taenia solium requires transmission between humans and pigs. The disease is considered to be eradicable, but data on attempts at regional elimination are lacking. We conducted a three-phase control program in Tumbes, Peru, to determine whether regional elimination would be feasible.
HG-64DEVELOPMENT OF IN VIVO DRUG AND GENE DELIVERY SYSTEMS TO BRAIN TUMOR USING LIPOSOMAL NANOCARRIERS
Authors: Madhuri Kambhampati, Jamila Gittens, Sridevi Yadavilli, S. Balakrishna Pai, Kathleen M. McNeeley, Oren J. Becher, Roger J. Packer, Ravi Bellamkonda, Rohan Fernandes, Javad Nazarian
Journal: Neuro-Oncology (2016)
QOS-25A STUDY OF CHILDHOOD CANCER SURVIVORS' ENGAGEMENT WITH LONG-TERM FOLLOW-UP CARE
Authors: Nicky Thorp, Katherine Knighting, Lucy Bray, James Hayden, Laura Elder, Kate Hancock, Therese Otty, Julian Hampton-Matthews, Lynda Appleton, Michelle Wright
Journal: Neuro-Oncology (2016)

QOS-25. A STUDY OF CHILDHOOD CANCER SURVIVORS’ ENGAGEMENT WITH LONG-TERM FOLLOW-UP CARE Nicky Thorp1, Katherine Knighting2, Lucy Bray2, James Hayden3, Laura Elder1, Kate Hancock1, Therese Otty1, Julian Hampton-Matthews1, Lynda Appleton1, and Michelle Wright3; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Merseyside, UK; Edge Hill University, Merseyside, UK; Alder Hey Children’s Hospital NHS Foundation Trust, Liverpool, Merseyside., UK In the UK, there are now over 40,000 adult survivors of childhood tumours. However, approximately two-thirds are at risk of continuing substantial illness, impairment and limitations due to adverse late effects of the cancer or treatment received in childhood. To improve their health and well-being, it is essential that they have the opportunity to access an appropriate survivorship multi-agency service to advise and aid in the management of late effects. However, these clinics have high rates of non-attendance and it is challenging to encourage continued engagement with the service by those who arewell and cancer-free. This project sought to examine the perceptions of childhood cancer survivors of a Late Effects Clinic (LEC) via a paper questionnaire using closed and Likert scale questions and open text responses. From the 458 questionnaires posted, 113 were returned (24.7 % response rate). Of these 25[KK1] % had a primary diagnosis of a CNS tumour[KK2] . The majority of respondents had used the LEC on at least 2 occasions (89%, n 1⁄4 101). Most respondents were ‘satisfied’ or ‘very satisfied’ with their LEC appointment (73%, n1⁄4 83) and felt that it was very important to attend LEC (86%, n 1⁄4 97). Not all respondents felt fully informed of the purpose of attending the LEC (21%, n 1⁄4 24) or knowledgeable of their potential late effects and test results (31%, n 1⁄4 35) even though they rated this as very important (89%, n 1⁄4 101). Barriers to attending LEC were given as work commitments (36%, n 1⁄4 43) and the distance to the clinic (40%, n 1⁄4 48). Neuro-Oncology 18:iii145–iii158, 2016. doi:10.1093/neuonc/now081.25 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
EPN-07IMPACT OF CHROMOSOMAL ABERRATIONS AND MOLECULAR SUBTYPE ON TELOMERASE ACTIVATION IN PEDIATRIC EPENDYMOMA
Authors: Johannes Gojo, Daniela Lötsch, Sabine Spiegl-Kreinecker, Kristian Pajtler, Katharina Neumayer, Pia Korbel, Asuka Araki, Thomas Mohr, Susanne Gröbner, Stefan Pfister, Thomas Czech, Martin Filipits, Marcel Kool, Andreas Peyrl, Christine Haberler, Walter Berger, Irene Slavc
Journal: Neuro-Oncology (2016)
Sixty seconds on . . . minimum alcohol price
Authors: Bryan Christie
Journal: BMJ (2016)

Nowhere near, in UK terms. In 2012 the coalition government pledged support for a minimum price for a unit of alcohol but shelved its plans in 2013, claiming that there was not enough evidence to proceed.1 2 But Scotland did pass legislation to set a minimum unit price there, also in 2012.3

Not much, apart from growth in lawyers’ yacht and luxury holiday funds.

The drinks industry launched a legal challenge to the policy in the Scottish courts. …